I'd love it if the FDA used this meeting to also provide info on the EUA, but there's nothing in this quote that definitively says the meeting will be about both. Nader could easily be saying he looks forward to ALSO meeting about the EUA at some future point.

Short version: let's make sure we don't get carried away and set ourselves up for disappointment.

Quote:

---

"We also look forward to meeting with the FDA to help expedite the resubmission of our BLA, as well as learning whether we receive Emergency Use Approval for leronlimab for COVID-19 or, alternatively, are required to proceed with a Phase 3 trial." (CYDY PR)

---